Amid the COVID-19 crisis, the global market for Intranasal Drug Delivery estimated at US$44.7 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027. Spray, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$19.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drop segment is readjusted to a revised 5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $12.1 Billion, While China is Forecast to Grow at 6.3% CAGR
The Intranasal Drug Delivery market in the U.S. is estimated at US$12.1 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$11.8 Billion by the year 2027 trailing a CAGR of 6.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.
Gel Segment to Record 3.6% CAGR
In the global Gel segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$8 Billion in the year 2020 will reach a projected size of US$10 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.8 Billion by the year 2027, while Latin America will expand at a 4.5% CAGR through the analysis period.
This report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others:
Aegis Therapeutics LLC
AptarGroup, Inc.
AstraZeneca Plc
Becton Dickinson and Company
GlaxoSmithKline Plc
Johnson & Johnson
Marina Biotech, Inc.
MedImmune, Inc.
Merck & Co., Inc.
Nemera
Novartis AG
OptiNose US Inc.
Pfizer Inc.
Valeant Pharmaceuticals International, Inc.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 and a Looming Global Recession
A Prelude
Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
Recent Market Activity
Factors Inhibiting Nose-to-Brain Transportation of Drugs
Bioavailability: An Important Facet of Intranasal Drug Delivery
Outlook
Nasal Drug Delivery Devices & Equipment
Traditional Vs. Advanced Intranasal Drug Formulation Types
Global Competitor Market Shares
Intranasal Drug Delivery Competitor Market Share Scenario Worldwide (in %): 2018 & 2029
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
Intranasal Corticosteroids - A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
Innovation in Drug Delivery: A Talisman for Success
Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
Controlled Release Technology Is the Buzz Word
Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
Tight Junction Biology: A Key Speed Breaker in Commercialization
RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery
Growing Interest for Preservative-free Nasal Spray Formulations
Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Results
For the year ended January 31, 2024, the Company's revenues decreased by $139,027,000 to $578,945,000 compared to $717,972,000 recorded for the year ended January 31, 2023, a decrease of 19.4%. This decrease is mainly explained by the...
Lendistry announces today that it has been selected to administer the Entertainment Business Interruption Fund Program (BIF) to support small Los Angeles County businesses serving the entertainment industry. This program, created and funded through...
Rocky Mountain Liquor Inc. (the "Company" or "Rocky Mountain"), listed on the TSX Venture Exchange (the "Exchange"), today reported its financial results for the full year and fourth quarter ended December 31, 2023.KEY...
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") announces a brokered, best-efforts Listed Issuer Financing Exemption private placement (the "Offering") consisting of units of the Company (the "Units") at a price of C$0.20 per Unit (the...
Customers Bancorp, Inc. :
First Quarter 2024 Highlights
Q1 2024 net income available to common shareholders was $45.9 million, or $1.40 per diluted share; ROAA was 0.94% and ROCE was 12.08%.
Q1 2024 core earnings* were $46.5 million, or $1.42...
Petrolympic Ltd. (the "Company", TSXV: PCQ) wishes to announce it has completed a non-brokered private placement (the "Offering") of 5,000,000 common shares of the Company on a flow-through basis ("FT Shares") at a price of $0.08 per FT Share, for...